Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 761 to 770 of 2039

TitleReference numberPublishedLast updated
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA718
Secukinumab for treating active non-radiographic axial spondyloarthritisTA719
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA714
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failedTA715
Enzalutamide for treating hormone-sensitive metastatic prostate cancerTA712
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA275
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillationTA249
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillationTA256

Results per page

  1. 10
  2. 25
  3. 50
  4. All